# colorectal cancer - claude-opus-4-8

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 45542
- Completion tokens: 16406
- Reasoning tokens: 0
- Total tokens: 61948
- API requests reported: 5
- Elapsed seconds: 305.268
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: Anthropic

---
# Multidimensional Interpretation of Transcriptomic Prognostic Signatures in Colorectal Cancer

## 1. Overall Biological Interpretation

The prognostic transcriptomic landscape in colorectal cancer reveals a multifaceted biology centered on **metabolic reprogramming, epithelial differentiation loss, stromal remodeling, and mitochondrial dysfunction**. The 100-gene signature divides into 54 risk-associated genes (HR > 1) and 46 protective-associated genes (HR < 1), with 71 genes reaching FDR ≤ 0.05, indicating robust statistical evidence.

The protective genes converge on **mitochondrial energy metabolism** (ATP23, NDUFA9, CS, ATP5B, ATP5G1), **intestinal epithelial differentiation** (CDX2, MYB, LGALS4), and **one-carbon/amino acid metabolism** (ASL, MCCC2, GLYCTK, ILVBL). These signatures suggest that tumors retaining oxidative metabolism and differentiated epithelial identity have better outcomes.

Conversely, risk-associated genes reflect **stromal activation and ECM remodeling** (INHBB, SCARA3, DCBLD2, ITGBL1, ADAMTS18), **oncogenic signaling** (AKT3, ABL2, ZEB1-AS1), and **dedifferentiation programs** (MIR31HG, NR2F1-AS1). The prominence of INHBB (HR = 1.433, FDR = 0.001093), a TGF-β superfamily member, points to activated stromal-epithelial crosstalk driving poor prognosis.

This is not simply a proliferation-versus-quiescence dichotomy. Instead, it represents a **metabolic-structural axis** where protective metabolic competence opposes risk-associated stromal reprogramming and epithelial plasticity.

---

## 2. Core Biological Programs

### **Program 1: Mitochondrial Oxidative Metabolism — Protective**

**Direction**: Protective (HR < 1)

**Supporting genes**: ATP23 (HR = 0.69, FDR = 0.006636), NDUFA9 (HR = 0.69, FDR = 0.008647), CS (HR = 0.75, FDR = 0.03875), ATP5B (HR = 0.75, FDR = 0.05931), ATP5G1 (HR = 0.75, FDR = 0.05194), TIMM13 (HR = 0.75, FDR = 0.03938)

**Pathways**: 
- GO: Oxidative phosphorylation, mitochondrial ATP synthesis
- Reactome: Complex I biogenesis (NDUFA9), TCA cycle (CS)
- KEGG: Oxidative phosphorylation

**Evidence**:
Multiple independent mitochondrial genes spanning **Complex I** (NDUFA9), **ATP synthase subunits** (ATP23, ATP5B, ATP5G1), **TCA cycle** (CS, citrate synthase), and **mitochondrial import machinery** (TIMM13) collectively indicate that tumors maintaining oxidative phosphorylation have better survival. ATP23 is a mitochondrial protease required for ATP synthase assembly. NDUFA9 is a core Complex I subunit. CS catalyzes the first TCA cycle step. Their concordant protective direction (all HR < 0.75) suggests **metabolic fitness** as a prognostic determinant.

GTEx records confirm high expression of these genes in normal colon tissue. Literature (PMID 17135288) links ATP23 to mitochondrial quality control. The protective effect likely reflects **differentiated epithelial metabolism** and lower reliance on glycolysis-driven invasive phenotypes.

**Strength**: Strong. Multiple independent genes, well-defined pathways, mechanistic coherence.

**Limitations**: Observational association. Cannot distinguish whether mitochondrial function is causally protective or a marker of differentiated, less aggressive tumors. Tumor heterogeneity may obscure cell-type-specific contributions (epithelial vs stromal mitochondria).

---

### **Program 2: Epithelial Differentiation and Intestinal Identity — Protective**

**Direction**: Protective (HR < 1)

**Supporting genes**: CDX2 (HR = 0.75, FDR = 0.0355), MYB (HR = 0.77, FDR = 0.01924), LGALS4 (HR = 0.77, FDR = 0.05123), PRR15L (HR = 0.80, FDR = 0.03939), GJB6 (risk, HR = 1.29, FDR = 0.03938 — gap junction loss)

**Pathways**:
- GO: Epithelial cell differentiation, intestinal epithelial cell development
- Reactome: CDX2-mediated transcriptional regulation
- KEGG: Wnt signaling (CDX2 inhibits Wnt/β-catenin)

**Evidence**:
CDX2 is a master regulator of intestinal epithelial identity. Its protective effect (HR = 0.75) is mechanistically grounded: CDX2 suppresses Wnt/β-catenin signaling by transactivating GSK-3β and Axin2 (PMID 30631044), directly opposing colorectal tumorigenesis. MYB, a hematopoietic/epithelial transcription factor, is protective (HR = 0.77), consistent with differentiated crypt epithelium. LGALS4 (galectin-4) is an intestinal differentiation marker. PRR15L is expressed in differentiated colonocytes.

The risk-associated gene GJB6 (connexin 30, HR = 1.29) suggests **gap junction disruption** accompanies dedifferentiation, impairing coordinated epithelial function.

HPA records show CDX2 high expression restricted to colon/rectum. ClinVar and GWAS data link CDX2 variants to colorectal cancer risk. The protective signal reflects **retention of differentiated epithelial programs** that constrain malignant progression.

**Strength**: Strong. CDX2 has direct mechanistic literature in colorectal cancer. Multiple independent differentiation markers converge.

**Limitations**: CDX2 expression can be heterogeneous within tumors and lost in poorly differentiated regions. The prognostic effect may be confounded by tumor grade/stage. Expression does not distinguish cause from consequence of better differentiation.

---

### **Program 3: Stromal Activation and TGF-β/ECM Remodeling — Risk**

**Direction**: Risk (HR > 1)

**Supporting genes**: INHBB (HR = 1.43, FDR = 0.001093), SCARA3 (HR = 1.38, FDR = 0.002434), DCBLD2 (HR = 1.41, FDR = 0.008647), ITGBL1 (HR = 1.30, FDR = 0.03061), ADAMTS18 (HR = 1.26, FDR = 0.04681), NPR3 (HR = 1.35, FDR = 0.01642)

**Pathways**:
- GO: Extracellular matrix organization, TGF-β signaling, collagen remodeling
- Reactome: ECM proteoglycans, integrin signaling
- KEGG: TGF-β pathway, focal adhesion
- Hallmark: Epithelial-mesenchymal transition

**Evidence**:
INHBB encodes inhibin βB, a TGF-β superfamily ligand. Its top-ranked risk effect (HR = 1.43, FDR = 0.001093) is supported by recent literature (Europe PMC 41992239): "High INHBB expression in colorectal cancer is associated with poor prognosis and drives malignant phenotypes in tumor cells." INHBB promotes stromal activation, angiogenesis, and immune suppression.

SCARA3 (scavenger receptor, HR = 1.38) is a macrophage/fibroblast marker linked to tumor-associated stroma. DCBLD2 (discoidin/neuropilin-like, HR = 1.41) modulates TGF-β and VEGF signaling. ITGBL1 (integrin β-like 1, HR = 1.30) mediates ECM-cell interactions. NPR3 (natriuretic peptide receptor C, HR = 1.35) is expressed in cancer-associated fibroblasts and modulates stromal signaling.

These genes collectively indicate **activated desmoplastic stroma** and **ECM remodeling**, hallmarks of aggressive colorectal cancer. The stromal compartment supports invasion, metastasis, and therapy resistance.

**Strength**: Very strong. Top-ranked gene (INHBB) with direct functional literature. Multiple independent stromal/ECM genes. Mechanistically coherent with known biology of aggressive colorectal cancer.

**Limitations**: Expression may reflect stromal contamination rather than intrinsic tumor biology. Bulk RNA-seq cannot distinguish tumor-intrinsic vs microenvironment contributions. Stromal signatures are prognostic but not necessarily targetable in epithelial tumors.

---

### **Program 4: Oncogenic Signaling (PI3K/AKT and ABL pathways) — Risk**

**Direction**: Risk (HR > 1)

**Supporting genes**: AKT3 (HR = 1.32, FDR = 0.03875), ABL2 (HR = 1.30, FDR = 0.02757), LRRC8A (HR = 1.38, FDR = 0.02501), PTPN14 (HR = 1.36, FDR = 0.02501)

**Pathways**:
- KEGG: PI3K-Akt signaling, gastric cancer, melanoma
- Reactome: Signaling by receptor tyrosine kinases
- GO: Regulation of cell proliferation, apoptotic process

**Evidence**:
AKT3 is a PI3K/AKT pathway isoform. Its risk association (HR = 1.32) suggests **PI3K/AKT activation** drives poor outcomes in colorectal cancer, consistent with known roles in proliferation, survival, and therapy resistance. AKT3 is upregulated in multiple cancers and confers resistance to apoptosis.

ABL2 (HR = 1.30) is a non-receptor tyrosine kinase regulating cytoskeleton and cell migration. Its risk effect suggests **enhanced motility and invasive capacity**. LRRC8A (volume-regulated anion channel, HR = 1.38) modulates cell volume, proliferation, and apoptosis. PTPN14 (protein tyrosine phosphatase, HR = 1.36) is a regulator of Hippo/YAP signaling; paradoxically, it can act as tumor suppressor or oncogene depending on context, but here its high expression associates with risk, possibly reflecting compensatory upregulation or context-dependent oncogenic roles.

STRING network analysis shows AKT3 interactions with PI3K pathway members. cBioPortal records show AKT3 amplification/mutation in colorectal cancer cohorts. The convergence of AKT3, ABL2, and phosphatase/kinase regulators indicates **dysregulated kinase signaling** underpinning aggressive phenotypes.

**Strength**: Moderate to strong. AKT3 and ABL2 are well-established oncogenic drivers. Pathway coherence is clear.

**Limitations**: PI3K/AKT is a broad pathway. The specific contribution of AKT3 vs AKT1/2 isoforms is unclear. PTPN14's role is context-dependent and its risk association may reflect complex regulatory feedback. No direct functional validation in this cohort.

---

### **Program 5: Amino Acid and One-Carbon Metabolism — Protective**

**Direction**: Protective (HR < 1)

**Supporting genes**: ASL (HR = 0.74, FDR = 0.0355), MCCC2 (HR = 0.74, FDR = 0.02823), GLYCTK (HR = 0.71, FDR = 0.02034), ILVBL (HR = 0.72, FDR = 0.03294), ACSS2 (HR = 0.76, FDR = 0.06021), DNPEP (HR = 0.73, FDR = 0.03608)

**Pathways**:
- KEGG: Glyoxylate and dicarboxylate metabolism, amino acid metabolism (valine/leucine/isoleucine degradation)
- GO: Arginine biosynthesis, branched-chain amino acid catabolism
- Reactome: Metabolism of amino acids

**Evidence**:
ASL (argininosuccinate lyase, HR = 0.74) catalyzes the penultimate step in arginine biosynthesis. MCCC2 (methylcrotonyl-CoA carboxylase, HR = 0.74) is essential for leucine catabolism. GLYCTK (glycerate kinase, HR = 0.71) participates in serine metabolism. ILVBL (branched-chain amino acid metabolism, HR = 0.72) supports valine/leucine/isoleucine degradation. DNPEP (aspartyl aminopeptidase, HR = 0.73) cleaves N-terminal acidic residues in peptide processing.

These genes collectively indicate **functional amino acid and one-carbon metabolism**, essential for nucleotide synthesis, redox balance, and differentiated metabolic programs. Tumors with intact amino acid metabolism may be less reliant on glycolysis and glutaminolysis, reflecting lower metabolic plasticity and invasiveness.

HMDB records confirm metabolite connections. GTEx shows high colon expression of ASL and MCCC2. The protective effect likely reflects **metabolic differentiation** and reduced metabolic flexibility, constraining adaptation to nutrient stress.

**Strength**: Moderate. Multiple independent metabolic enzymes converge on amino acid pathways. Mechanistically plausible.

**Limitations**: Metabolic reprogramming is complex and context-dependent. Protective effect could reflect differentiated cell-of-origin rather than direct metabolic constraint. No direct functional validation. Overlaps with mitochondrial program (ILVBL interacts with mitochondrial enzymes), so may not be fully independent.

---

## Summary

The five core programs—**mitochondrial metabolism (protective), epithelial differentiation (protective), stromal activation (risk), oncogenic signaling (risk), and amino acid metabolism (protective)**—capture the major biological themes with minimal redundancy. The strongest evidence supports **mitochondrial function**, **CDX2-driven differentiation**, and **INHBB-mediated stromal activation** as independent prognostic determinants. Oncogenic signaling and metabolic programs are well-supported but somewhat overlapping with the mitochondrial/differentiation axis.

The data collectively suggest that **metabolically competent, differentiated tumors with low stromal activation** have better survival, while **stromal-rich, dedifferentiated, and metabolically plastic tumors** drive poor outcomes. This framework is actionable: therapies targeting stromal signaling (TGF-β inhibitors), restoring differentiation (CDX2 agonists, if feasible), or exploiting metabolic dependencies (targeting glycolysis in low-OXPHOS tumors) may improve outcomes.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=74, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Anthropic / claude-opus-4-8

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
